Bulk Pharmaceutical API Sources for TERLIVAZ

Bulk Pharmaceutical API Sources for TERLIVAZ

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		72081
ABI Chem		AC1L2HDP
ABI Chem		AC1Q5JB2

Bulk Active Pharmaceutical Ingredient (API) Sources for TERLIVAZ

Last updated: July 27, 2025

Introduction
Terlivaz (vedolizumab) is a monoclonal antibody used predominantly to treat ulcerative colitis and Crohn's disease. As a biologic therapy, the manufacturing of Terlivaz involves complex processes centered around sourcing high-quality Active Pharmaceutical Ingredients (APIs). Ensuring reliable API supply chains is essential for manufacturing, regulatory compliance, and maintaining patient safety. This article examines the primary sources and considerations for procuring bulk APIs for Terlivaz.

---

Understanding the API Supply Chain for Biologics like Terlivaz
Unlike small-molecule drugs, biologics such as vedolizumab are produced through biotechnological processes involving living cells. The API for Terlivaz is a recombinant monoclonal antibody generated using mammalian cell culture systems. Sourcing involves securing the plasmids, cell lines, bioreactors, and purification components, with suppliers typically specializing in biologic-grade materials compliant with Good Manufacturing Practices (GMP).

---

Key Components of API Sourcing for Terlivaz

1. Cell Line Development and Supply
   The backbone for any biologic like Terlivaz lies in the genetically engineered cell lines producing the monoclonal antibody. Chinese Hamster Ovary (CHO) cells are most commonly used globally:

• Cell Banks and Master Cell Banks (MCB):
  Suppliers such as Lonza, Thermo Fisher Scientific, and Cell and Gene Therapy Catapult provide GMP-compliant MCBs that are the foundation for API manufacturing.

• Cell Line Validation:
  Ensures the stability, purity, and consistent production of the monoclonal antibody.

2. Plasmid DNA and Vectors
   The genetic sequences encoding vedolizumab are housed in plasmid vectors. Reputable suppliers include:

• Cytiva (GE Healthcare): Provides GMP-grade plasmids optimized for stable expression.
• BioLabs or Addgene: Offer research-grade plasmids, but for GMP manufacturing, commercial-grade plasmids are mandatory.

3. Bioreactor and Fermentation Media
   High-quality media are vital:

• Custom-biotech suppliers: Such as Lonza and Thermo Fisher provide chemically defined, animal-origin-free media suitable for GMP biologic production.

4. Purification Components and Resin
   Affinity chromatography resins are central to isolation:

• Cytiva (Sepharose resin), Pall Corporation, and GE Healthcare: Offer GMP-grade Protein A affinity resins, crucial for monoclonal antibody purification.

5. Fill-Finish and Packaging Materials
   For final formulation, sourcing sterile vials, stoppers, and syringes meets stringent quality standards:

• Leading suppliers: Schott glass, West Pharmaceutical Services for high-quality, GMP-compliant containers.

---

Regional and Global API Suppliers

North America
The United States and Canada host numerous GMP-certified suppliers of biologic APIs:

• Lonza: Major provider of cell lines, media, and bioprocessing equipment.
• Thermo Fisher Scientific: Supplies plasmids, media, and purification resins.
• Biosimilar contract manufacturing organizations (CMOs): Such as Catalent and Patheon.

Europe
Europe offers a mature biotech manufacturing infrastructure:

• Cytiva (formerly GE Healthcare): Supplies resins, media, and cell bank components.
• Merck KGaA: Provides raw materials and bioprocessing solutions.

Asia-Pacific
Emerging as significant players in API sourcing:

• WuXi Biologics, Samsung Biologics: Offer end-to-end bioprocessing services and bulk APIs.
• BioDuro-Sundia: Provides biosimilar development and manufacturing services.

India
Known for cost-effective biologics manufacturing:

• Biocon, Dr. Reddy’s Laboratories: Hold capacities for monoclonal antibody production under GMP standards.

China
Expanding API manufacturing capabilities:

• Sino Biopharmaceuticals, BeiGene: Engaged in biologics R&D and production.

---

Key Considerations in API Sourcing

• Regulatory Compliance:
  Suppliers must meet stringent GMP regulations set by agencies such as the FDA, EMA, and PMDA.

• Quality Assurance & Control:
  Rigorous testing for purity, potency, and biosafety (e.g., viral clearance) is mandatory.

• Supply Chain Security:
  Establish multiple supply sources to mitigate risks associated with geopolitical issues, manufacturing delays, or shortages.

• Intellectual Property (IP):
  Ensure contractual clarity regarding confidentiality and licensing, especially for proprietary cell lines or genetic sequences.

• Cost versus Quality Balance:
  While cost-efficiency is critical, compromising quality could jeopardize regulatory approval and patient safety.

---

Emerging Trends in API Sourcing for Monoclonal Antibodies

• Single-Use Bioreactors:
  Reduce contamination risk and streamline manufacturing, impacting API sourcing strategies.

• Process Modularization:
  Facilitates rapid scale-up and flexibility in sourcing from multiple suppliers.

• Localization Strategies:
  Manufacturers increasingly prefer regional API sources to reduce lead times and improve supply stability amidst geopolitical tensions.

---

Conclusion
Sourcing high-quality bulk APIs for Terlivaz implicates a complex web comprising cell line development, plasmid quality, raw materials for bioprocessing, and purification components. The primary sources span North America, Europe, and Asia-Pacific, each with established, GMP-compliant suppliers. Ensuring regulatory adherence, supply chain robustness, and high-quality standards remains fundamental in maintaining uninterrupted production of Terlivaz.

---

Key Takeaways

• Biologic API sourcing for Terlivaz hinges on reliable, GMP-compliant suppliers of cell lines, plasmids, media, and purification resins.
• Major regions supplying APIs include North America, Europe, and Asia-Pacific, each with leading biologic manufacturing capabilities.
• Establishing diversified supplier networks mitigates risks associated with supply disruptions.
• Ongoing innovations such as single-use bioreactors and regional manufacturing facilities augment sourcing flexibility.
• Regulatory compliance, quality assurance, and IP management are critical components of sourcing strategies.

---

FAQs

1. What are the primary raw materials used in producing the API for Terlivaz?
The production involves GMP-grade cell lines (CHO cells), expression vectors (plasmids), culture media (animal-free, chemically defined), and purification resins (Protein A affinity media).

2. How do regulatory agencies influence API sourcing for biologics like Terlivaz?
Regulators mandate GMP compliance, rigorous quality testing, and traceability. Suppliers must maintain certification standards such as FDA-validated processes and EMA GMP compliance to ensure regulatory approval and safe production.

3. Are there risks in sourcing APIs internationally?
Yes. Risks include supply chain disruptions, geopolitical issues, differing regulatory standards, and quality variability. Companies mitigate these through multi-sourcing and strict quality audits.

4. How does regional manufacturing capacity affect API sourcing?
Regional capacities influence lead times, cost, and supply reliability. Companies increasingly prefer localized sourcing to ensure timely access and reduce logistical complexities.

5. What role do contract manufacturing organizations (CMOs) play in API supply chains?
CMOs often provide end-to-end manufacturing, including the expansion and purification of APIs, offering scalable capacity, regulatory expertise, and supply chain continuity.

---

References
[1] "Biologic APIs: Sourcing and Manufacturing," Pharma Intelligence, 2022.
[2] "GMP Guidelines for Biologic Materials," European Medicines Agency, 2021.
[3] "Biologics Production: Cell Line and Upstream Processes," Nature Biotechnology, 2020.
[4] "Sourcing Strategies in Biopharmaceuticals," Pharmaceutical Technology, 2021.
[5] "The Role of CMOs in Biologics Manufacturing," BioPharm International, 2019.